SUVN-911 - 10mM in DMSO , CAS No.2414674-71-6

CAS: 2414674-71-6 Cat. No.: S656387 Fórmula: C₁₁H₁₄Cl₂N₂O Peso molecular: 261.15 PubChem CID: 146026958

GRADE & PURITY 10mM in DMSO

Storage

Desiccated,Store at -80°C

Shipped In

Dry ice packs + Cold packs

Descripción general

SUVN-911 is a potent, selective, brain penetrated and orally bioavailable neuronal nicotinic acetylcholine α4β2 receptor antagonist, with a K i of 1.5 nM. SUVN-911 has antidepressant activity

In Vitro

SUVN-911 displays high selectivity for α4β2 over α3β4 nAChR. SUVN-911 shows good selectivity against over 70 receptors which includes GPCRs, ion channels, enzymes, peptides, steroids, second messengers, growth factors and prostaglandins. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

SUVN-911 is devoid of cardiovascular and gastrointestinal side effects . SUVN-911 (1.0-10.0 mg/kg; p.o.; daily; for 3 days) shows significant antidepressant effects . SUVN-911 shows metabolic stability in rats . SUVN-911 (3 mg/kg; p.o.) has shown high oral exposures, longer half-lives and adequate brain penetration in Wistar rats . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Wistar rats (180-230 g) Dosage: 1 mg/kg, 3 mg/kg, 10.0 mg/kg Administration: Oral administration, daily, for 3 days Result: Showed antidepressant like activity with no signs of tachyphylaxis. Animal Model: Male Wistar rats (225 ± 25 g) Dosage: 3 mg/kg (Pharmacokinetic Analysis) Administration: Oral administration Result: AUC=3507 ng*h/mL, T 1/2 =3.34 hours.

IC50& Target:Ki: 1.5 nM (α4β2 receptor)

Specifications

Especificaciones y pureza

10mM in DMSO

Mecanismos bioquímicos y fisiológicos

SUVN-911 is a potent, selective, brain penetrated and orally bioavailable neuronal nicotinic acetylcholine α4β2 receptor antagonist, with a K i of 1.5 nM. SUVN-911 has antidepressant activity.

Condiciones de almacenamiento de almacenamiento

Desiccated,Store at -80°C

Enviado en

Dry ice packs + Cold packs

Este producto requiere envío en cadena de frío. Los servicios terrestres y otros servicios económicos no están disponibles.

Nombres e identificadores

Isómeros SMILES

C1[C@H]2C[C@H]2N[C@@H]1COC3=CN=C(C=C3)Cl.Cl

CAS alternativo

2414674-71-6

PubChem CID

146026958

Peso molecular

261.15

Application Protocols

No manufacturer-validated protocols are provided for SUVN-911. The following general guidance supports typical small-molecule screening workflows.

• Stock preparation: Dissolve in anhydrous DMSO to 10–50 mM. Vortex and sonicate if necessary; avoid heating above 40°C. If particulates persist, centrifuge or filter through 0.2 µm PTFE.
• Plate handling: Use low-bind plates and pre-wet pipette tips with vehicle to improve volume accuracy at low microliter transfers. Maintain consistent DMSO content across wells.
• Dose–response: Prepare 10-point, 3-fold serial dilutions (or as required) maintaining constant vehicle %; include vehicle-only controls and positive controls where applicable.
• Assay interference checks: Evaluate compound autofluorescence/absorbance at instrument wavelengths; include detergent controls if aggregation is a concern.
• Data quality: Run technical triplicates; monitor Z′ factor for plate performance. Track precipitation visually and with light scattering if available.
• Storage of working plates: If plates must be pre-dosed, seal with solvent-resistant films and store at −20°C to −80°C desiccated; minimize freeze–thaw.

Always adapt to the specific biology and readout. Document solvent lots, plate maps, and timing between dosing and readout for reproducibility.

Biological Roles

Item-specific biological target, pathway engagement, or mechanism of action for SUVN-911 is not provided in this listing. No assumptions about pharmacology should be made without corroborating structural and bioactivity data.

General guidance for discovery use

• Treat SUVN-911 as a research-only small molecule for screening and exploratory biology. Confirm identity and purity via CoA before biological studies.
• If a putative target is known from independent literature, verify lot-to-lot consistency and reproduce baseline activity in the reported assay format prior to downstream experiments.
• Profile basic in vitro parameters early: aqueous solubility at relevant pH, chemical stability in assay buffer, nonspecific binding (to plastic, serum proteins), and potential assay interference (fluorescence, absorbance, redox reactivity).
• For cell-based work, assess cytotoxicity/viability across the intended concentration range and solvent carryover. Monitor precipitation visually and by light scattering.

Data integrity

• Record exact stock concentration, solvent, and dilution scheme. Include negative/vehicle controls and, where applicable, orthogonal assay readouts to rule out artifacts.

Note: This product is supplied strictly for research use only. No medical, diagnostic, veterinary, or clinical applications are supported or implied.

Buffer Applications

SUVN-911 is not a buffer component. However, it is commonly necessary to deliver small-molecule library members into biological buffers for assays.

Practical considerations (general)

• Vehicle: Prepare a concentrated DMSO stock (e.g., 10–50 mM), then dilute into assay buffer (e.g., PBS, HBSS, HEPES-buffered media) keeping final DMSO ≤0.1–0.5% v/v when feasible.
• Precipitation control: Add compound stock last, with vigorous mixing. If precipitation occurs, consider modest surfactants compatible with your assay (e.g., 0.01–0.05% Tween-20) or use cyclodextrin carriers; validate against assay readout.
• pH: If ionizable, solubility often increases when buffer pH is adjusted relative to pKa; pKa is not specified here—confirm experimentally.
• Protein binding: High serum or albumin content can reduce free fraction; consider protein-free controls and measure unbound concentration if relevant.
• Adsorption: To minimize loss to plastics, use low-bind plates and tubes or glass vials for intermediate dilutions.

Quick recipe example (general)

• 10 mM DMSO stock → 1:1000 into buffer yields 10 µM with 0.1% DMSO final. Mix thoroughly; inspect for haze or particulates; if present, decrease final concentration or adjust vehicle composition.

Always document buffer composition, pH, and vehicle percentage in reports to ensure reproducibility.

Green Alternatives

Because SUVN-911 is a screening compound (not a process solvent or bulk reagent), “green alternatives” primarily concern the choice of dissolution and handling solvents rather than replacement of the compound itself.

Considerations for greener practices

• Prefer ethanol or isopropanol over DMF/NMP when chemically compatible and when aqueous dilution tolerates alcohols. These are less hazardous and more volatile for recovery.
• Use DMSO judiciously: widely accepted in assays, but minimize final assay concentration (≤0.1–0.5% v/v) to reduce environmental load and biological interference.
• Explore aqueous buffer with cyclodextrins or PEG 400/water blends to reduce reliance on dipolar aprotic solvents; verify assay compatibility.
• Scale: Keep stock solutions highly concentrated to minimize total solvent volume and waste.

Illustrative comparison (general)

• DMSO: high solvency, broad assay compatibility; not “green” but practical at small scale.
• Ethanol: greener, fast-evaporating; limited solubility for very lipophilic compounds.
• DMF/NMP: strong solvency; avoid when possible due to reproductive toxicity and disposal concerns.

Operational green tips

• Use micro-aliquots to avoid freeze–thaw and disposal of unused thawed stocks.
• Implement solvent recycling for alcohol rinses where permitted.
• Plan parallel solubility screens to adopt the least hazardous solvent system that still meets assay needs.

Pharmaceutical Uses

No pharmacopeial status, excipient role, or manufacturing use is provided for SUVN-911. This item is supplied for research use only and is not intended for formulation development for clinical applications.

General, non-clinical context

• Screening compounds like SUVN-911 may be used in early discovery to explore structure–activity relationships and target validation in preclinical research settings. Any translation to dosage forms would require extensive additional data (identity, purity profile, stability, safety), which are not provided here.

If pursuing preformulation research (laboratory only)

• Determine solid-state form (amorphous vs crystalline, polymorph), hygroscopicity, and thermal behavior (DSC/TGA) to understand stability.
• Evaluate pKa, logP/logD, and solubility profile (pH–solubility) for hypothetical salt formation or enabling formulations (e.g., cyclodextrins, lipid-based systems) in non-clinical experiments.
• Assess chemical stability in proposed vehicles (DMSO, ethanol, buffer blends) under assay conditions (light, temperature, oxygen).

Compliance note

• Do not use in humans or animals for therapeutic or diagnostic purposes. No statements herein should be construed as clinical guidance.

Physical Properties

Item-specific physicochemical properties are not provided in this listing.

• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Melting point: Not specified for this item; refer to CoA/Spec Sheet.
• Boiling point: Not applicable/not specified for this solid library compound; refer to CoA/Spec Sheet if available.
• Density: Not specified for this item; refer to CoA/Spec Sheet.
• Refractive index: Not applicable for solids; not specified for this item.
• pKa/logP/logD: Not specified for this item; refer to CoA/Spec Sheet.
• Solubility: Not specified for this item; typical practice for discovery compounds is dissolution in anhydrous DMSO to prepare concentrated stocks (e.g., 10–50 mM), followed by dilution into assay buffer. Verify with CoA.

Notes for planning (general, literature-based best practice)

• If structure is later available, compute cLogP, pKa, and polar surface area to anticipate aqueous solubility and ionization state for assay buffers.
• Perform a small-scale solubility screen across dry DMSO, DMF, ethanol, and 50% PEG 400/H2O to identify a robust stock solution. Filter or centrifuge to remove undissolved solids before dosing.
• Record exact solvent lot and concentration; adsorption to plastics can occur for lipophilic/aromatic compounds—prefer glass vials for concentrated stocks.

Quality and Grades

• Grade/purity: Not specified for this item; refer to CoA/Spec Sheet.
• Appearance: Not specified for this item; refer to CoA/Spec Sheet.

Context and expectations for small-molecule library items

• Discovery-library compounds are typically provided at research grade with assay-suitable purity (commonly ≥95% by HPLC/LC-MS), but this is not guaranteed for this item. Verify acceptance criteria and analytical data (HPLC trace, MS, NMR if available) on the CoA.
• UV cutoff, residual solvents, water content (KF), and metal/peroxide limits are not specified here; consult the CoA for any lot-specific details.

What “research use only” means

• Supplied strictly for laboratory R&D. Not for diagnostic, clinical, veterinary, or food/cosmetic use. No GMP status is implied.

Stabilizers and form

• No stabilizer or salt-form information is provided. If salt form, counterion identity and residual inorganic content should be verified on the CoA. If free base/acid, consider salt screening to improve solubility or stability in your workflow.

Recommendations

• Request a recent CoA and, if required, a full analytical package (HPLC method, reference chromatogram, LC-MS, NMR) before high-value studies.
• On receipt, document lot, purity, and any visual observations; retain a reference sub-aliquot for future cross-checks.

Reaction and Applications

This product is offered as a ready-to-test small-molecule library member rather than a synthetic reagent or building block. No manufacturer reaction guidance or functional-group reactivity is provided for SUVN-911.

Accordingly:

• Not typically used as a stoichiometric reagent, ligand, or catalyst in preparative chemistry.
• No item-specific roles in named reactions are available from the product data.

If your intent is synthetic derivatization or SAR expansion:

• Obtain the structure and functional-group map (from CoA or literature) before attempting modifications (e.g., N-alkylation, amide coupling, cross-coupling). Unknown liabilities such as sensitive halides, acetal/oxime groups, or redox-labile motifs may limit conditions.
• Start with microscale transformations and LC-MS monitoring to assess stability under bases, acids, oxidants, and reductants.

Applications aligned with library usage (general)

• Primary/secondary screening in biochemical or cell-based assays.
• Target deconvolution workflows (e.g., CETSA, DARTS, chemoproteomics) once structure and suitable handles are known.
• PhysChem profiling (solubility, permeability, microsomal stability) to triage activity hits.

Summary: Treat SUVN-911 as a screening compound for discovery biology rather than as a general-purpose reagent. For reaction planning, verified structural information is essential.

Reaction Conditions

No item-specific reaction conditions are applicable because SUVN-911 is supplied as a screening compound rather than a reagent, and its functional groups are not disclosed in this listing.

General guidance if conducting exploratory chemistry (only after structure is verified)

• Solvents: Dry DMSO, DMF, MeCN, toluene, or alcohols as dictated by functional groups; maintain anhydrous/inert conditions for air- or moisture-sensitive motifs.
• Temperatures: Begin at ambient; escalate in 10–20°C increments while monitoring by LC-MS. Avoid >80°C in polar aprotics without stability data.
• Catalysts/bases/acids: Choose mild conditions first (e.g., Pd-catalyzed couplings with weak bases; organic bases for amide formation; buffered conditions for acylations of sensitive heterocycles).
• Times/yields: Establish with microscale scouting; no literature yields are available for this item in the current listing.

For biological assay preparation

• Stock solution preparation in DMSO at 10–50 mM, followed by serial dilutions in assay buffer, is typical. Validate stability and absence of precipitation throughout the dosing period.

Safety and Handling

GHS and hazard information for SUVN-911 are not provided in this listing.

• Signal word: Not specified for this item; refer to SDS.
• H-statements / GHS classification / pictograms: Not specified for this item; refer to SDS.

General laboratory safety (best practice)

• Handle in a fume hood with standard PPE: lab coat, safety glasses, and suitable gloves (e.g., nitrile). Avoid inhalation of dust and contact with skin/eyes.
• Storage incompatibilities: Until structure is confirmed, avoid strong oxidizers and strong acids/bases. Keep material dry and under inert atmosphere if feasible to limit hydrolysis/oxidation.
• Weighing/dosing: Minimize static and aerosolization; for hygroscopic or potent materials, weigh quickly in a desiccated environment or glove box. Use microspatulas and antistatic tools.
• First aid (overview; defer to SDS): In case of skin/eye contact, rinse with water for at least 15 minutes; remove contaminated clothing. If inhaled, move to fresh air. If ingested, rinse mouth. Seek medical attention.
• Waste: Collect dissolved and solid waste in designated organic waste streams per institutional and local regulations.

Critical note

• Always consult the product-specific SDS for authoritative hazard, toxicology, and emergency information prior to first use. Absent explicit data, treat as a compound of unknown hazard with conservative controls.

Solvent Selection

Without disclosed structure, initial dissolution strategy should prioritize robust, assay-compatible solvents.

Recommended approach

• Primary stock solvent: Anhydrous DMSO is the default for small molecules due to high solvating power and assay compatibility at ≤0.1–1% v/v final.
• Secondary options: DMF, NMP, ethanol (EtOH), or isopropanol (IPA) for molecules that resist DMSO. For aqueous delivery, consider co-solvent systems: 10–30% EtOH or 5–20% DMSO in buffer, or PEG 400 blends.
• Aqueous compatibility: If ionizable, adjust buffer pH one unit above (for bases) or below (for acids) the pKa to enhance solubility—pKa not specified here, so confirm experimentally.

Practical tips

• Perform a tiered solubility check (1 mg in 50–100 µL solvent) with sonication and mild heating (<40°C). Avoid prolonged heating that may induce degradation.
• Filter 0.2 µm PTFE or centrifuge stocks to remove particulates. Verify concentration by UV-Vis if a clean chromophore is evident, or by quantitative NMR.
• Adsorption: Hydrophobic/aromatic compounds may bind plastics—prefer amber glass vials for concentrated DMSO stocks.

Selection versus alternatives (general guidance)

• DMSO: highest success rate; potential assay interference at high %.
• EtOH/IPA: greener and volatile; limited by aqueous tolerance and protein stability.
• PEG 400/water: good for very lipophilic compounds; higher viscosity, may affect assay readouts.

Storage and Reconstitution

Item-specific conditions

• Storage: Desiccated, Store at −80°C (per product data). Protect from moisture and, if structure suggests sensitivity, from light (amber vials recommended as a precaution).
• Shipping: Dry ice packs + Cold packs (per product data) to maintain low temperature.

Handling on receipt

• Allow the sealed container to equilibrate to room temperature in a desiccator before opening to prevent moisture condensation.
• Immediately re-cap under dry atmosphere (dry box or nitrogen purge) after withdrawing material. Reseal with parafilm and return to −80°C storage.

Reconstitution (general guidance)

• Prepare a high-concentration stock in anhydrous DMSO (e.g., 10–50 mM). Record exact mass and solvent volume; mix by vortex and brief sonication. If needed, warm gently to 30–40°C; avoid prolonged heating.
• Clarify by centrifugation or 0.2 µm PTFE filtration. Aliquot into single-use volumes (e.g., 10–50 µL) in amber glass vials or low-bind tubes.
• Store aliquots at −80°C, desiccated. Avoid repeated freeze–thaw cycles; discard aliquots after one thaw unless stability has been verified.

Stability notes

• No formal stability data are provided for this item; verify stability in your chosen solvent and at working temperature by LC-MS/HPLC.
• Document storage dates, number of freeze–thaw events, and visual appearance. Replace stocks if discoloration, precipitation, or unexpected assay drift is observed.

Structure and Identity

• Product name: SUVN-911 (SKU: S656387)
• CAS: 2414674-71-6
• PubChem CID: 146026958
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.

Structural features

• Item-specific structure is not provided in this listing. If you require 2D/3D structure, stereochemistry, or functional group annotation (e.g., heteroaromatics, amides, basic centers), please consult the Certificate of Analysis (CoA), Specification Sheet, or the referenced PubChem entry.

2D structure description (general guidance)

• In the absence of a disclosed structure, treat SUVN-911 as a proprietary small-molecule screening compound. Many library compounds contain one or more heteroaromatic rings, amine-bearing scaffolds, and polar functional handles to balance solubility and permeability; however, no such assumptions should be made for experimental planning without verified structural data for this exact item.

Synthetic Utility

SUVN-911 is offered as a screening compound; no functional-group map or reactivity profile is provided. Therefore, it is not positioned as a general synthetic intermediate in this catalog entry.

If derivatization is contemplated (general advice)

• Obtain the exact structure and assess reactive handles (e.g., aryl halides for cross-coupling, anilines/phenols for acylation/alkylation, carboxylates for amide formation). Without this information, avoid speculative transformations.
• Start with small-scale trials (≤5 mg) under mild, orthogonal conditions to probe stability to acid/base, nucleophiles/electrophiles, and redox reagents.
• Monitor by LC-MS to map degradation pathways and to confirm mass balance.

Typical transformations for drug-like scaffolds (literature, general)

• Amide coupling (HATU/EDC) if a carboxylate or amine is present.
• Buchwald–Hartwig or Suzuki–Miyaura couplings if aryl halides/boronates are available.
• Reductive amination for carbonyl–amine elaboration on aliphatic or heteroaromatic frameworks.

Conclusion

• Without item-specific structure, SUVN-911 should be treated primarily as a probe compound, not a building block. Request structural documentation from the CoA/literature before planning any synthetic campaigns.

Target Specificity

No target, binding partner, enzyme/receptor specificity, or selectivity profile is provided for SUVN-911 in this listing. Accordingly, no claims are made regarding potency, selectivity, or off-target liabilities.

Recommendations

• If a target is proposed from independent literature, confirm with orthogonal assays and, where possible, counter-screens to establish selectivity.
• Acquire or generate dose–response curves (with proper vehicle controls) and report full assay conditions to ensure reproducibility.

Note: All use is strictly for research. No diagnostic or clinical claims are made or implied.